<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35938771</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1750-8460</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>British journal of hospital medicine (London, England : 2005)</Title><ISOAbbreviation>Br J Hosp Med (Lond)</ISOAbbreviation></Journal><ArticleTitle>Mast cell activation syndrome and the link with long COVID.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>10</EndPage><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12968/hmed.2022.0123</ELocationID><Abstract><AbstractText>Mast cells are innate immune cells found in connective tissues throughout the body, most prevalent at tissue-environment interfaces. They possess multiple cell-surface receptors which react to various stimuli and, after activation, release many mediators including histamine, heparin, cytokines, prostaglandins, leukotrienes and proteases. In mast cell activation syndrome, excessive amounts of inflammatory mediators are released in response to triggers such as foods, fragrances, stress, exercise, medications or temperature changes. Diagnostic markers may be difficult to assess because of their rapid degradation; these include urinary N-methyl histamine, urinary prostaglandins D<sub>2</sub>, DM and F<sub>2&#x3b1;</sub> and serum tryptase (which is stable) in the UK. Self-management techniques, medications and avoiding triggers may improve quality of life. Treatments include mast cell mediator blockers, mast cell stabilisers and anti-inflammatory agents. 'Long COVID' describes post-COVID-19 syndrome when symptoms persist for more than 12 weeks after initial infection with no alternative diagnosis. Both mast cell activation syndrome and long COVID cause multiple symptoms. It is theorised that COVID-19 infection could lead to exaggeration of existing undiagnosed mast cell activation syndrome, or could activate normal mast cells owing to the persistence of viral particles. Other similarities include the relapse-remission cycle and improvements with similar treatments. Importantly, however, aside from mast cell disorders, long COVID could potentially be attributed to several other conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arun</LastName><ForeName>Soumya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Biosciences, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mast Cell Action, Leamington Spa, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Storan</LastName><ForeName>Abbie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mast Cell Action, Leamington Spa, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Science, Engineering, and Environment, The University of Salford, Salford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Bethan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Haematology Department, University Hospitals of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Hosp Med (Lond)</MedlineTA><NlmUniqueID>101257109</NlmUniqueID><ISSNLinking>1750-8460</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>820484N8I3</RegistryNumber><NameOfSubstance UI="D006632">Histamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006632" MajorTopicYN="N">Histamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090267" MajorTopicYN="Y">Mast Cell Activation Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008407" MajorTopicYN="N">Mast Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Mast cell activation syndrome</Keyword><Keyword MajorTopicYN="N">Multiple symptomatology</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae SARS-CoV-2 infection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>8</Day><Hour>8</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35938771</ArticleId><ArticleId IdType="doi">10.12968/hmed.2022.0123</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>